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AbstrACt
Objective To determinate the prevalence and correlates 
of cardiometabolic multimorbidity (CMM), and their cross-
country variation among individuals with hypertension 
residing in rural communities in South Asia.
Design A cross-sectional study.
setting Rural communities in Bangladesh, Pakistan and 
Sri Lanka.
Participants A total of 2288 individuals with hypertension 
aged ≥40 years from the ongoing Control of Blood 
Pressure and Risk Attenuation- Bangladesh, Pakistan and 
Sri Lanka clinical trial.
Main outcome measures CMM was defined as the 
presence of ≥2 of the conditions: diabetes, chronic kidney 
disease, heart disease and stroke. Logistic regression was 
done to evaluate the correlates of CMM.
results About 25.4% (95% CI 23.6% to 27.2%) of the 
hypertensive individuals had CMM. Factors positively 
associated with CMM included residing in Bangladesh 
(OR 3.42, 95% CI 2.52 to 4.65) or Sri Lankan (3.73, 95% 
CI 2.48 to 5.61) versus in Pakistan, advancing age (2.33, 
95% CI 1.59 to 3.40 for 70 years and over vs 40–49 
years), higher waist circumference (2.15, 95% CI 1.42 
to 3.25) for Q2–Q3 and 2.14, 95% CI 1.50 to 3.06 for 
Q3 and above), statin use (2.43, 95% CI 1.84 to 3.22), 
and higher levels of triglyceride (1.01, 95% CI 1.01 to 
1.02 per 5 mg/dL increase). A lower odds of CMM was 
associated with being physically active (0.75, 95% CI 0.57 
to 0.97). A weak inverted J-shaped association between 
International Wealth Index and CMM was found (p for non-
linear=0.058), suggesting higher risk in the middle than 
higher or lower socioeconomic strata.
Conclusions CMM is highly prevalent in rural South 
Asians affecting one in four individuals with hypertension. 
There is an urgent need for strategies to concomitantly 
manage hypertension, cardiometabolic comorbid 
conditions and associated determinants in South Asia.
IntrODuCtIOn
Cardiometabolic multimorbidity (CMM), 
defined as the coexistence of two or more of 
the following chronic conditions (diabetes, 
heart disease, stroke and chronic kidney 
disease (CKD)), is being increasingly 
recognised as a global public health chal-
lenge.1 2 Compared with a single cardiomet-
abolic disease, multimorbidity from these 
conditions is associated with multiplicative 
risk of mortality and cognitive decline.1 3
Individuals from South Asia have been 
shown to be more susceptible to cardiometa-
bolic and other chronic conditions compared 
with other ethnic groups.4 5 In part, this is 
postulated to be due to higher visceral fat 
mass as South Asians have been shown to 
have higher amounts of abdominal adipose 
than Caucasians,6 7 and abdominal obesity is 
strengths and limitations of this study
 ► This study is the first to evaluate the prevalence and 
correlates of cardiometabolic multimorbidity (CMM) 
in a representative sample aged ≥40 years with hy-
pertension from rural communities in Bangladesh, 
Pakistan and Sri Lanka.
 ► Our study used a uniform study design, door-to-
door sampling of individuals, random selection of 
clusters, consistent definitions of variables and out-
comes (eg, standardised measurements of serum 
creatinine) and standardised study procedures in all 
three countries.
 ► A causal relationship between covariates and CMM 
cannot be inferred due to the cross-sectional design 
of the study.
 ► We did not have data on covariates such as health-
care access, dietary habit, psychological stress and 
physiological biomarkers, which may additionally 
explain cross-country variation in multimorbidity.
 ► Our findings may not be generalised to all rural-re-
siding hypertensive individuals aged 40 years and 
over in each country.
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better predictors for cardiovascular diseases (CVDs) risk 
and diabetes than body mass index (BMI).8 Furthermore, 
most of South Asia is still rural with significant dispari-
ties in access to healthcare, and mortality from CVD has 
shown to be higher than in urban areas.9 However, the 
prevalence and correlates of CMM in rural South Asian 
countries have not been reported.
Therefore, we analysed baseline data from the ongoing 
Control of Blood Pressure and Risk Attenuation- Bangla-
desh, Pakistan and Sri Lanka (COBRA-BPS) trial on 2288 
hypertensive individuals in rural communities in Bangla-
desh, Pakistan and Sri Lanka with the following objectives: 
(1) To examine the prevalence of CMM, (2) to determine 
the sociodemographic characteristics, lifestyle factors and 
clinical risk factors associated with CMM. We also sought 
to determine whether BMI or waist circumference was a 
stronger determinant of CMM in this population.
We hypothesised that: (1) the prevalence of CMM is 
high, and varies among hypertensive individuals in rural 
communities across the three South Asian countries; (2) 
the cross-country variation in CMM will only partially be 
accounted for by differences in sociodemographic, life-
style and clinical risk factors and (3) waist circumference 
will be more strongly associated with CMM than BMI.
MethODs
Population
The present study was performed using the baseline data 
from COBRA-BPS full-scale study. The study methodology 
has been described previously.10 Briefly, COBRA-BPS 
full-scale study is an ongoing 2-year cluster randomised 
controlled trial among 2643 hypertensive adults from 
30 randomly selected rural clusters (communities), 10 
clusters each, in Bangladesh, Pakistan and Sri Lanka. In 
each country, clusters selection was stratified by distance 
(≤2.5 km for near and >2.5 for far) from the government 
primary care clinics such that there were six near and four 
far clusters in each country. Individuals in each cluster 
were screened using door-to-door sampling method. The 
inclusion criteria for COBRA-BPS were age ≥40 years, 
hypertension (defined as a sustained elevation of systolic 
blood pressure (BP) to ≥140 mm Hg, or diastolic BP to 
≥90 mm Hg based on two readings from 2o separate days, 
or receiving antihypertensive medications), and residents 
in the selected clusters. Individuals were excluded if 
they had severe physical incapacity, were pregnant, had 
advanced diseases (on dialysis, liver failure and other 
systemic diseases) or mentally comprised leading to the 
incapability of giving consent.
Online supplementary figure S1 shows the study flow 
diagram. Of the 2977 hypertensive individuals from 30 
randomly selected clusters in 3 countries, 2643 were 
enrolled in the clinical trial after excluding 334 individuals 
for various reasons (see online supplementary figure S1). 
Of the 2643 hypertensives recruited, 355 (13.4%) were 
excluded because they missed data on diabetes (n=217), 
CKD (n=289) and heart disease (n=64), leaving 2288 for 
the final analysis. The study protocol was approved by the 
relevant Ethical Review Committee in Singapore, Bangla-
desh, Pakistan, Sri Lanka, and the UK. All study partici-
pants provided written informed consent.
Measurements
Sociodemographic variables were age (40–49, 50–59, 
60–69, 70 and over years), gender, education (formal vs 
informal education) and marital status (married vs single, 
divorced or widowed). Economic status was assessed by 
International Wealth Index (IWI).11 IWI is based on a 
household’s ownership of selected assets, access to basic 
service and characteristics of the house and is estimated 
by principal component analysis. The score of IWI ranges 
from 0 to 100 and, in the current study, was classified 
into four groups via its quartiles (IWI<43, 43≤IWI<60, 
60≤IWI<73 and IWI≥73). Lifestyle factors included 
smoking status (current smoker vs non-current smoker) 
and physical activity. Physical activity was evaluated by 
the short version of the International Physical Activity 
Questionnaire12 and was classified as inactive, minimally 
active and highly active. BMI was calculated as weight (in 
kilogram)/height (in metres)2 and was categorised as 
underweight (BMI <18.5), normal (18.5≤BMI<23), over-
weight (23≤BMI<27.5) and obesity (BMI ≥27.5).13 Waist 
circumference was grouped into four categories using 
the gender-specific quartiles (for male ≤82, 82–91, 91–98, 
≥98 cm, for female ≤79, 79–88, 88–95 and ≥95 cm). Heart 
disease was ascertained based on self-reported physician 
diagnosis of angina, heart attack and heart failure. Stroke 
was determined according to WHO definition.14 Family 
history of CVD was determined according to self-reported 
family history of heart disease or stroke.
An overnight fasting blood sample was collected to 
measure serum creatinine (measured on Beckman DU), 
lipids (measured on Roche Hitachi-912) and plasma 
glucose (measured on Beckman Synchron Cx-7/Delta) 
in each country. Serum creatinine measurements were 
calibrated to isotope dilution mass spectrometry trace-
able values. Urine albumin and creatinine excretion were 
measured on spot urine samples by nephelometry using 
the Array Systems method on a Beckman Coulter. All tests 
were done in an accredited laboratory in each country. 
Although no variability study was done for the tests, all 
three laboratories conformed to international standards 
for diagnostics. Diabetes was defined as a fasting plasma 
glucose ≥126 mg/dL or self-reported use of antidiabetic 
medication. CKD was defined as the presence of estimated 
glomerular filtration rate (GFR) ≤60 mL/min/1.73 m2 or 
urine albumin and creatinine ratio (UACR) ≥30 mg/g. 
GFR was estimated using the original CKD- Epidemiology 
Collaboration equation.15 UACR was determined by urine 
albumin divided by urine creatinine.
statistical analysis
The outcome measurement of this study was the pres-
ence of CMM, defined as having two or more of the 
following cardiometabolic conditions: diabetes, CKD, 
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heart disease and stroke. CKD was included in the defini-
tion because it has a strong association with CVD due to 
traditional cardiovascular risk factors (eg, hypertension 
and diabetes), and kidney-specific risk factors (eg, dyslipi-
daemia, anaemia and low-grade inflammation).16
The comparison of characteristics between individuals 
with and without CMM was performed using indepen-
dent sample t-test for continuous variables and χ2 test for 
categorical variables. When continuous variables were not 
normally distributed, Mann-Whitney U test was used. We 
used Cochran-Armitage trend test to measure the asso-
ciation of waist circumference categories with different 
measurements of cardiometabolic conditions—indi-
vidual and multimorbid.
We fitted generalised estimating equation logistic regres-
sion models with an exchangeable correlation matrix for 
CMM to account for the hierarchical nature of the data 
within the villages (clusters) in each country. ORs and 
95% CIs were presented. Covariates considered clinically 
relevant or found to be associated with CMM in previous 
literature or in the current bivariate analysis at p<0.15 
were included in the multivariate models. Three models 
were built by sequentially entering the covariates in three 
individual blocks. In model 1, only country was included; 
in model 2, we included age, gender, education, marital 
status, IWI and BMI besides country; in the last model, 
we additionally added physical activity, smoking, waist 
circumference, family history of CVD, statin use, high-den-
sity lipoprotein (HDL), low-density lipoprotein (LDL) 
and triglyceride. Total cholesterol was not included in the 
model due to its strong correlation with LDL (Pearson 
correlation coefficient=0.90). Because adjusted analysis 
suggested possible non-linear associations of CMM with 
IWI and waist circumference, we further examined their 
associations with the restricted cubic splines by model-
ling the two covariates as continuous variables.17 We used 
‘%RCS_Reg’ SAS macro18 to perform adjusted analysis 
with five knots (5%, 25%,50%,75% and 95% percentiles) 
specified.
We also investigated two-way interactions between 
country and other variables in the last model to assess the 
presence of a country-specific effect. Significant interac-
tions were interpreted by the ratio of ORs (RORs)19 and 
subgroup analysis by country.
All analyses were conducted using SAS V.9.4, and all 
hypothesis testing was two tailed with p<0.05 set as statisti-
cally significant.
Patient and public involvement statement
Patients and public were not involved in the conception, 
design or interpretation of this study.
results
baseline characteristics
The baseline characteristics of 2288 individuals with 
hypertension are shown in table 1. The overall prevalence 
of CMM was 25.3% (n=581). The mean (SD) age was 59.0 
(11.3) years; 64.3% (n=1471) were female. The mean 
(SD) BMI and waist circumference were 24.7 (5.0) kg/m2 
and 88.2 (12.8) cm, respectively.
Individuals with CMM were older, better educated, 
less likely to be married and had higher IWI scores than 
were those without. They also had lower levels of phys-
ical activity, higher BMI, higher waist circumference and 
elevated levels of triglyceride, and were more likely to 
have a family history of CVD, to be Sri Lankan and statin 
users. In contrast, no other baseline characteristics were 
associated with CMM (table 1).
Online supplementary table S1 shows the character-
istics of individuals included (n=2288) and excluded 
(n=355) from the current analysis. Compared with indi-
viduals excluded, those included had higher education, 
higher IWI score, higher levels of physical activity, and 
were more likely to have a family history of CVD, reside 
in Bangladesh and Sri Lanka, and use statin. Country-spe-
cific baseline characteristics are summarised in online 
supplementary tables S2–4.
CMM conditions
Table 2 shows bivariate associations between various 
measurements of cardiometabolic conditions and waist 
circumference quartiles. Hypertensive individuals with 
a single additional cardiometabolic condition and 
three or more cardiometabolic conditions accounted 
for 35.3% (95% CI 33.3% to 37.3%) and 5.6% (95% CI 
4.7% to 6.7%), respectively. CKD was the most prevalent 
cardiometabolic condition (38.3%, 95% CI 36.3% to 
40.3%).
CMM and waist circumference
The prevalence of CMM increased across the first three 
quartile groups of waist circumference, and slightly 
dropped in the highest quartile (p value for linear trend 
<0.001) (table 2). We also observed a significant linear 
trend for three or more cardiometabolic conditions, 
diabetes, heart disease and stroke, but not for CKD 
(table 2). Corresponding country-specific results are 
reported in online supplementary tables S5–7. CMM 
was most prevalent among participants from Sri Lanka 
(36.3%, 95% CI 33.0% to 39.8%), followed by those from 
Bangladesh (27.4%, 95% CI 24.3% to 30.5%) and Paki-
stan (10.2%, 95% CI 8.0% to 12.7%).
The bivariate associations between morbidity pairs 
and waist circumference are presented in online supple-
mentary table S8. The most frequently observed pair was 
diabetes and CKD (10.1%, 95% CI 8.9% to 11.4%), and 
least observed was diabetes and stroke (1.2%, 95% CI 
0.8% to 1.7%). An increasing trend across the quartile 
groups of waist circumference was observed for coex-
isting diabetes and CKD (p for linear trend <0.001). 
Diabetes and CKD were also the most prevalent pair in all 
three countries, but the prevalence of other pairs in each 
country differed from that of the whole sample and each 
other (see online supplementary tables S9–11).
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Table 1 Baseline characteristics by status of cardio-metabolic multimorbidity* (n=2288)
Characteristics All
Cardiometabolic multimorbidity
P valueYes (n=581) No (n=1707)
Age (y), n (%) <0.001
  40–49 566 (24.7) 92 (15.8) 474 (27.8) .
  50–59 633 (27.7) 138 (23.8) 495 (29.0) .
  60–69 660 (28.8) 203 (34.9) 457 (26.8) .
  70 and over 429 (18.8) 148 (25.5) 281 (16.5) .
Male, n (%) 817 (35.7) 217 (37.3) 600 (35.1) 0.34
Formal education (vs informal), n (%) 1396 (61.0) 431 (74.2) 965 (56.5) <0.001
Married (vs others), n (%) 1679 (73.4) 399 (68.7) 1280 (75.0) 0.003
International Wealth Index score, n (%) <0.001
  0–43 539 (23.6) 83 (14.3) 456 (26.8) .
  43–60 596 (26.1) 158 (27.2) 438 (25.7) .
  60–73 555 (24.3) 159 (27.4) 396 (23.3) .
  73 and above 591 (25.9) 180 (31.0) 411 (24.2) .
Current smoker (vs current non-smoker), n (%) 236 (10.3) 55 (9.5) 181 (10.6) 0.44
Physical activity level (MET-min/week), n (%) <0.001
  Inactive 603 (26.7) 157 (27.5) 446 (26.4) .
  Minimally active 512 (22.7) 164 (28.7) 348 (20.6) .
  Highly active 1144 (50.6) 250 (43.8) 894 (53.0) .
BMI (kg/m2), n (%) 0.001
  <18.5 204 (8.9) 29 (5.0) 175 (10.3) .
  18.5–23.0 656 (28.7) 166 (28.7) 490 (28.8) .
  23.0–27.5 849 (37.2) 231 (39.9) 618 (36.3) .
  27.5 and above 573 (25.1) 153 (26.4) 420 (24.7) .
Waist circumference† (cm), n (%) <0.001
  0–Q1 543 (23.8) 93 (16.0) 450 (26.4) .
  Q1–Q2 570 (24.9) 139 (24.0) 431 (25.3) .
  Q2–Q3 554 (24.2) 174 (30.0) 380 (22.3) .
  Q3 and above 619 (27.1) 174 (30.0) 445 (26.1) .
Family history of CVD, n (%) 593 (26.5) 177 (31.3) 416 (24.9) 0.003
Country, n (%) <0.001
  Bangladesh 819 (35.8) 224 (38.6) 595 (34.9) .
  Pakistan 679 (29.7) 70 (12.0) 609 (35.7) .
  Sri Lanka 790 (34.5) 287 (49.4) 503 (29.5) .
HDL (mg/dL), mean (SD) 45.3 (12.8) 45.3 (12.8) 45.3 (12.8) 0.98
Triglyceride (mg/dL), median (IQR) 128.7 (94.0,183.0) 132.8 (99.3,192.0) 127.0 (91.8,179.1) <0.001
Total cholesterol (mg/dL), mean (SD) 194.6 (48.5) 197.4 (52.0) 193.6 (47.2) 0.12
LDL (mg/dL), mean (SD) 124.4 (40.6) 124.0 (43.8) 124.5 (39.4) 0.82
Statin use, n (%) 315 (13.8) 156 (26.9) 159 (9.3) <0.001
*For male ≤82, 82–91, 91–98, ≥98 cm, for female ≤79, 79–88, 88–95, ≥95 cm.
†Cardiometabolic multimorbidity was defined as as the presence of two or more chronic conditions of diabetes, heart disease, CKD and stroke.
BMI, body mass index;CKD, chronic kidney disease; CVD, cardiovascular disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MET, 
metabolic equivalent of task.
Factors associated with CMM
In multivariate-adjusted analysis, living in Bangladesh or 
Sri Lanka (vs Pakistan), older age, higher IWI, higher 
waist circumference, statin use and elevated levels of 
triglyceride were significantly associated with a higher 
odds of CMM, while being physically active was associated 
with a lower odds of CMM (model 3 in table 3). BMI was 
not significantly associated with CMM in model 3. The 
evaluation for interaction showed that country signifi-
cantly modified the associations between CMM and four 
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Table 3 Multivariate predictors of cardiometabolic multimorbidity among hypertensive individuals in rural Bangladesh, 
Pakistan and Sri Lanka
Variables
Model 1 (n=2288) Model 2 (n=2275) Model 3 (n=2191)
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
Country <0.001 <0.001 <0.001
  Pakistan 1.00 1.00 1.00
  Bangladesh 3.28 (2.41 to 4.47) <0.001 3.22 (2.41 to 4.29) <0.001 3.42 (2.52 to 4.65) <0.001
  Sri Lanka 4.98 (3.76 to 6.58) <0.001 3.40 (2.50 to 4.63) <0.001 3.73 (2.48 to 5.61) <0.001
Age (year) <0.001 <0.001
  40–49 1.00 1.00
  50–59 1.35 (0.99 to 1.86) 0.060 1.29 (0.94 to 1.77) 0.12
  60–69 2.08 (1.51 to 2.86) <0.001 1.82 (1.31 to 2.53) <0.001
  70 and over 2.59 (1.81 to 3.70) <0.001 2.33 (1.59 to 3.40) <0.001
Gender 0.32 0.58
  Male 1.00 1.00
  Female 0.86 (0.63 to 1.16) 0.32 0.92 (0.67 to 1.25) 0.58
Education 0.046 0.17
  Informal 1.00 1.00
  Formal 1.29 (1.00 to 1.64) 0.046 1.20 (0.93 to 1.56) 0.17
Marital status 0.15 0.18
  Single or widowed or divorced 1.00 1.00
  Married 0.82 (0.63 to 1.08) 0.15 0.82 (0.62 to 1.10) 0.18
International Wealth Index score 0.025 0.014
  0–43 1.00 1.00
  43–60 1.60 (1.11 to 2.31) 0.012 1.63 (1.09 to 2.44) 0.018
  60–73 1.64 (1.14 to 2.36) 0.008 1.69 (1.12 to 2.55) 0.013
  73 and above 1.38 (0.93 to 2.04) 0.11 1.29 (0.84 to 1.97) 0.25
BMI (kg/m2) <0.001 0.24
  <18.5 1.00 1.00
  18.5–23.0 1.85 (1.30 to 2.65) <0.001 1.17 (0.78 to 1.76) 0.45
  23.0–27.5 2.13 (1.45 to 3.14) <0.001 0.90 (0.57 to 1.42) 0.65
  27.5 and above 2.44 (1.62 to 3.66) <0.001 0.89 (0.56 to 1.41) 0.61
Smoking 0.87
  Non-current smoker 1.00
  Current smoker 1.04 (0.66 to 1.64) 0.87
Physical activity level (MET-min/
week)
0.010
  Inactive 1.00
  Minimally active 0.97 (0.71 to 1.30) 0.82
  Highly active 0.75 (0.57 to 0.97) 0.029
Waist circumference* (cm) <0.001
  0–Q1 1.00
  Q1–Q2 1.43 (1.03 to 1.99) 0.033
  Q2–Q3 2.15 (1.42 to 3.25) <0.001
  Q3 and above 2.14 (1.50 to 3.06) <0.001
Family history of CVD 0.55
  No 1.00
  Yes 1.08 (0.84 to 1.37) 0.55
Statin use <0.001
  Non-user 1.00
Continued
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Variables
Model 1 (n=2288) Model 2 (n=2275) Model 3 (n=2191)
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
  User 2.43 (1.84 to 3.22) <0.001
HDL (mg/dL, per 5 mg/dL increase) 0.96 (0.89 to 1.02) 0.17
Triglyceride(mg/dL, per 5 mg/dL 
increase
1.01 (1.01 to 1.02) <0.001
LDL (mg/dL, per 5 mg/dL increase) 1.00 (0.98 to 1.01) 0.57
*For male ≤82, 82–91, 91–98, ≥98 cm, for female ≤79, 79–88, 88–95, ≥95 cm.
BMI, body mass index; CVD, cardiovascular disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MET, metabolic equivalent of task.
Table 3 Continued
Figure 1 Multiple-adjusted log (ORs) and 95% CIs of cardiometabolic multimorbidity with International Wealth Index Score. A 
was based on model 3 in table 3, while B was derived based on the model adjusted for only age and gender.
other covariates: age (p for interaction<0.001), history 
of CVD (p for interaction=0.012), HDL (p for interac-
tion=0.008) and statin use (p for interaction=0.006) (see 
online supplementary tables S12 and 13). These associa-
tions varied in strength but not direction across the three 
countries. Multivariable-adjusted restricted cubic spline 
analyses suggested no evidence of a non-linear association 
between waist circumference and CMM (p for non-linear 
trend=0.59 based on model 3) but a weak non-linear 
association between IWI and CMM (figure 1A, inverted 
J-shaped, p for non-linear trend=0.058 based on model 3, 
and figure 1B, p for non-linear trend=0.026 based on the 
model adjusted for only age and gender.
DIsCussIOn
Data on multimorbidity are limited from South Asian 
countries.20–25 This study is the first to evaluate the prev-
alence and correlates of CMM in a representative sample 
aged ≥40 years with hypertension from rural communi-
ties in Bangladesh, Pakistan and Sri Lanka. We observed 
an alarmingly high prevalence of CMM—up to 25%—in 
rural South Asians with hypertension, and it was higher 
in Sri Lanka than the other two countries. CKD was the 
most common comorbid condition, followed by diabetes, 
stroke and heart disease. CKD and diabetes dominated all 
the morbidity pairs, and were found in 10% of the popu-
lation with hypertension. Individuals residing in Bangla-
desh and Sri Lanka (vs Pakistan) had higher odds of 
CMM regardless of sociodemographics, economic status, 
lifestyles and clinical factors. Being older, lower levels of 
physical activity, higher waist circumference, lower levels 
of HDL and higher levels of triglyceride, each, were inde-
pendently associated with the presence of CMM. Waist 
circumference was a stronger correlate of CMM than 
BMI. An inverted J-shaped association was found between 
IWI and the odds of CMM. Our findings add to the 
current knowledge on the epidemiology of CMM in rural 
South Asians, and underscore the importance to develop 
prevention and treatment strategies to target individuals 
at risk of or with CMM.
There are very few reports on CMM from South Asia, 
and the types of conditions vary. In a study from urban 
areas of Delhi, Chennai and Karachi, 9.4% of adults aged 
≥20 years had two or more of hypertension, diabetes, 
heart disease, stroke and CKD.25 Our study in hyperten-
sive community dwellers from rural areas in three South 
Asian countries indicated a higher prevalence with one 
in four individuals having two additional cardiometabolic 
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comorbid conditions. CKD was the most prevalent 
comorbid condition, partially attributable to the high 
prevalence of diabetes and other factors,26 which deserves 
further study. The implications of findings are significant 
as health systems are more fragmented in rural compared 
with urban areas, highlighting the urgency to provide 
comprehensive services for vascular disease prevention 
and management in rural South Asia.
It is interesting that we found an inverted J-shaped asso-
ciation between socioeconomic status and CMM, which 
is in contrast with studies in developed countries showing 
that lower economic status was a risk factor for multimor-
bidity.27–29 Studies from low-income and middle- income 
countries show a positive association of chronic non-com-
municable diseases with a socioeconomic gradient.22 24 30 
However, the non-linear relationship of CMM in our study 
suggested that cardiometabolic risk was highest in those in 
the middle socioeconomic strata (SES), compared with the 
highest and the lowest quartile of SES. The latter finding 
may be suggestive of an early reversal of social gradient for 
CMM and is consistent with our earlier finding of higher 
odds of uncontrolled hypertension in this population,31 and 
other studies showing more rich patients receive treatment 
including antihypertensive medications in India.32
Our study demonstrated that waist circumference had 
a stronger association with CMM than BMI because waist 
circumference but not BMI was statistically significant in 
the fully adjusted model (model 3 in table 3) Earlier studies 
have shown a clear incremental association of abdominal 
obesity over BMI for non-fatal myocardial infarction, stroke, 
diabetes and CKD.33–36 Also, a strong association of renal 
function decline with central obesity and BMI has been 
reported in a recent meta-analysis of 39 general population 
cohorts from 40 countries.37 Taken together, our findings 
suggest that central obesity should probably be included in 
multimorbidity indices in Asians, and especially underscore 
the same for adults with hypertension.38
Our findings also showed a remarkable variation in 
the prevalence of CMM among the three countries, with 
the highest in Sri Lanka and the lowest in Pakistan. Both 
CKD and diabetes were much more prevalent in Sri 
Lanka than the other two countries, which was the main 
reason for the higher prevalence of multimorbidity in Sri 
Lanka. Moreover, the variation in the prevalence could 
not be fully explained by sociodemographics, economic 
status, lifestyles and clinical factors, suggestive of the 
presence of residual confoundings. CKD of unknown 
aetiology is more prevalent in Sri Lanka39 and could 
be caused by the interaction of multiple agents such as 
heavy metals, pesticides, native (ayurvedic) medications 
or infections.39 40
Our alarmingly high rate of CMM in rural South Asia 
has major implications for public health at the national, 
regional and global levels. Our findings call for urgent 
programme to institute preventive measures to address 
hypertension and associated multimorbidity in rural 
areas in these countries where poor access to treatment 
and high CVD mortality rates have been reported.9 41
The major strengths of our study are that we used a 
uniform study design, door-to-door sampling of individ-
uals, random selection of clusters, consistent definitions of 
variables and outcomes (eg, standardised measurements 
of serum creatinine), and standardised study procedures 
in all three countries. This study also has limitations. First, 
a causal relationship between covariates and CMM cannot 
be inferred due to the cross-sectional design of the study. 
Therefore, the observed association between obesity and 
CMM could be underestimated because multimorbidity 
can cause subsequent weight loss. Second, heart disease 
was ascertained based on self-reported physician diagnosis 
and stroke based on self-reported signs and symptoms of 
stroke, which may be subject to information bias. Third, 
we allocated equal weight to each chronic condition in 
terms of disease severity. In fact, the effects of multimor-
bidity on various domains of health are likely to depend 
on disease severity, the unique combination of diseases 
and access to treatment and support.42 Fourth, we did not 
have data on covariates such as healthcare access, dietary 
habit, psychological stress and physiological biomarkers, 
which may additionally explain cross-country variation 
in multimorbidity. However, the main objective of our 
study was to determine the prevalence and pattern of 
cardiometabolic comorbidity and key determinants, 
which was achieved. Finally, our study was not conducted 
in a nationally representative sample of hypertensive indi-
viduals in rural areas, and the findings may not be gener-
alised to all rural-residing hypertensive individuals aged 
≥40 years in each country.
In conclusion, our study shows an alarmingly high 
burden of CMM affecting one in four individuals with 
hypertension from rural communities in Bangladesh, Paki-
stan and Sri Lanka. Central obesity had a graded, positive 
association with CMM. IWI showed an inverted J-shaped 
relationship with CMM, with individuals in middle SES 
have a higher burden than those in the highest or lowest 
SES. Our findings suggest that the current single-disease 
paradigm in hypertension prevention and management 
needs to be broadened and incorporate the large and 
increasing burden of comorbidities in rural South Asia. 
The management strategies should be customised to indi-
vidual countries. Strategies to manage central obesity may 
be relevant to the prevention and management of CMM 
in rural South Asia.
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